UTHR UNITED THERAPEUTICS Corp Insider Trading

CFO James Edgemond sells 10,000 shares at $5.5M via scheduled 10b5-1 plan; retains 18,876 non-derivative shares plus 40,000 stock options

James Edgemond, CFO and Treasurer, executed 9 separate sales totaling 10,000 shares for $5,478,663.36 on 2026-06-01, pursuant to a pre-arranged 10b5-1 trading plan. The blended average price across all transactions was $547.87, compared to the current price of $540.05. His non-derivative holdings decline from 28,876 shares to 18,876 shares post-transaction, a reduction of 34.6% relative to pre-transaction holdings, though derivative holdings of 40,000 stock options remain intact. Across his cross-ticker track record, his prior sells averaged 90-day returns of -4.0%, while his same-ticker history at UTHR shows five prior sells on 2026-05-28 averaging 90-day returns between -3.0% and -4.7%. As this transaction is scheduled under a 10b5-1 plan rather than discretionary, the timing of the sales does not reflect real-time market judgment but rather a pre-established schedule.

CEO Rothblatt sells 9,500 shares for $5,205,104.61 under pre-arranged 10b5-1 plan on 2026-06-01

Martine A Rothblatt executed 9 separate sales totaling 9,500 shares for $5,205,104.61 on 2026-06-01 under a pre-arranged 10b5-1 trading plan adopted on 2025-11-07, reducing her non-derivative holdings from 50,013 shares to 40,513 shares. The blended average sale price of $547.91 compares to a current market price of $540.05 and the stock's 52-week high of $609.35. This is a scheduled divestiture under a pre-plan framework, not a discretionary timing decision; the insider maintains 126,410 shares in stock option holdings (Table II derivative securities). Her prior trades at UTHR across 5 separate sell transactions in May 2026 show negative 30-day and 90-day returns (-1.5% to -3.0%), consistent with her cross-ticker track record on 19 prior sells averaging -1.6% returns at both horizons.

Rothblatt (UTHR CEO) sells 9,500 shares for $5.3M via pre-arranged 10b5-1 plan on 2026-05-29

Martine Rothblatt, Chairperson & CEO of United Therapeutics, executed 12 separate sales totaling 9,500 shares for $5,261,365.38 on 2026-05-29 at a blended average price of $553.83. This transaction is part of a pre-arranged 10b5-1 trading plan adopted on 2025-11-07, making it scheduled rather than discretionary. Post-transaction, Rothblatt retains 40,513 shares in direct holdings plus 135,910 shares via stock option derivatives, representing a partial reduction of approximately 19.0% of pre-transaction non-derivative holdings. The sales occurred just two days after five consecutive sales at the same ticker (2026-05-27), each posting modestly negative 30- and 90-day returns (-1.5% to -3.0%), consistent with his broader cross-ticker sell record showing an average 90-day return of -1.6% across 19 prior sales. As a scheduled plan execution, this transaction carries no timing signal and should be evaluated in context of the CEO's ongoing structured capital management rather than as a discretionary conviction statement.

CFO sells 10,000 shares ($5.7M) in 10 tranches via scheduled 10b5-1 plan; retains 18,876 shares plus 50,000 options.

James Edgemond, CFO and Treasurer of United Therapeutics, executed 10 separate sales totaling 10,000 shares for $5,656,298.33 on 2026-05-28 at prices ranging from $561.48 to $570.50 (blended average $565.63). This transaction is part of a pre-arranged 10b5-1 trading plan, indicating scheduled execution rather than discretionary timing. Post-transaction, Edgemond retains 18,876 non-derivative shares (down 34.6% from 28,876 prior) plus 50,000 stock option holdings, meaning his overall economic exposure to UTHR remains substantial. His prior sales at UTHR show mixed near-term outcomes (90-day returns ranging from +0.1% to -0.8%), with no clear directional signal; his cross-ticker track record shows minimal average returns (-1.0% over 90 days after prior sells). The stock currently trades at $556.82, down 8.6% from its 52-week high of $609.35, suggesting he sold shares when prices were elevated relative to recent lows but below peak levels.

UTHR CEO Rothblatt sold 9,500 shares for $5.4M via 11 separate transactions on 2026-05-28; follows 5 prior same-ticker sells on 2026-05-27, now holds 40,513 shares post-sale.

Martine A Rothblatt, Chairperson & CEO, executed 11 separate sales totaling 9,500 shares for $5,373,592.40 on 2026-05-28 as part of a pre-arranged 10b5-1 trading plan adopted on 2025-11-07. This is part of a consecutive pattern: Rothblatt sold shares again on 2026-05-27 in 5 prior transactions (noted in SAME-TICKER HISTORY). These scheduled sales reduced her non-derivative holdings from 50,013 shares to 40,513 shares, a -19.0% reduction, though she retains 145,410 shares in stock options (Table II derivative holdings). The blended transaction price of $565.64 is near the current price of $556.82, reflecting minimal post-trade price movement. Her cross-ticker track record shows 19 prior sells with an average 90-day return of -1.6%, and her 5 same-ticker prior trades on 2026-05-27 all posted negative 30-day and 90-day returns (-1.5% to -3.0%). Because this transaction is scheduled under a 10b5-1 plan rather than discretionary, and because the insider retains substantial derivative holdings, the sale signals portfolio management within a predetermined framework rather than a conviction-driven exit.

CEO Rothblatt sells 9,500 shares for $5.5M via scheduled 10b5-1 plan on 2026-05-27

Martine A Rothblatt, Chairperson & CEO of United Therapeutics, executed 9 separate sales totaling 9,500 shares for $5,466,283.19 on 2026-05-27 under a pre-arranged 10b5-1 trading plan adopted on 2025-11-07. This represents a 19.0% reduction of her non-derivative holdings, from 50,013 shares to 40,513 shares. The blended average price across all transactions was $575.40. Her derivative holdings remain substantial at 154,910 stock options, meaning her overall economic exposure to the company remains material. The scheduled nature of this plan removes discretionary timing as an investment signal; this is a mechanistic execution of a pre-planned program rather than a response to current conditions. Her cross-ticker track record across 20 prior sells shows an average 90-day return of -0.5%, while her same-ticker history at UTHR across 5 prior trades in May 2026 is mixed (ranging from -0.8% to +0.7% over 90 days). The company reported revenue of $781,500,000.00 and net income of $274,900,000.00 in the latest quarter, with annual revenue growth of +10.6%.

CFO James Edgemond executes 15 sales totaling 10,000 shares for $5,729,358.55 under 10b5-1 plan

CFO James Edgemond sold 10,000 shares on 2026-05-26 across 15 separate transactions at prices ranging from $559.58 to $577.13, with a blended average of $572.94. This sale reduced his non-derivative holdings to 18,876 shares (-34.6% vs pre-transaction level of 28,876 shares), though derivative holdings of 60,000 stock options remain. The trade is part of a pre-arranged 10b5-1 trading plan, meaning the execution was scheduled rather than discretionary. His cross-ticker track record across 20 prior sells shows an average 90-day return of -1.0%, while his 5 same-ticker sales at UTHR show mixed near-term performance ranging from -0.8% to +0.1%. The company's fundamentals remain solid with $274.9M in net income and +10.6% annual revenue growth, and the stock is currently -5.1% from its 52-week high of $609.35.

Rothblatt executes 14 scheduled sales totaling 8,000 shares for $4.6M at UTHR under 10b5-1 plan; retains 40,513 shares plus 164,410 stock options.

Martine A Rothblatt, Chairperson & CEO, executed 14 separate sales totaling 8,000 shares for $4,579,017.69 on 2026-05-26, with sale prices ranging from $560.52 to $577.03. The filing also includes a single purchase of 1,500 shares at $575.96 for $863,947.35 on the same date. The net effect reduced her non-derivative holdings from 47,013 shares to 40,513 shares, a 13.8% reduction. Critically, this activity is part of a pre-arranged 10b5-1 trading plan adopted on 2025-11-07, meaning the trades are scheduled and not discretionary. Post-transaction, Rothblatt retains 164,410 shares in stock options (Table II derivative holdings), so her overall economic exposure to the company remains substantial. The stock currently trades at $578.43, only 5.1% below its 52-week high of $609.35, reflecting strong near-term performance; over the prior 90 days the stock has gained 8.1%. At fundamentals, UTHR shows solid operational health: $781.5M in revenue for the latest quarter, $274.9M net income, and annual revenue growth of 10.6%, with a P/E of 19.07 and market cap of $24.6B. The scheduled nature of the sales precludes characterization of insider timing or conviction shifts; the narrative is one of routine capital execution under a pre-planned program.

CEO Rothblatt sells 9,500 shares for $5.4M via scheduled 10b5-1 plan on 2026-05-22

Martine A Rothblatt, Chairperson & CEO of United Therapeutics, executed 7 separate sales totaling 9,500 shares for $5,393,558.28 at blended average price $567.74 on 2026-05-22, reducing non-derivative holdings from 50,013 to 40,513 shares (-19.0%). The filing discloses this transaction is part of a pre-arranged 10b5-1 trading plan adopted on 2025-11-07, meaning the sales were scheduled and not discretionary. Post-transaction, Rothblatt retains 40,513 non-derivative shares and holds 173,910 derivative shares (stock options). The stock currently trades at $578.43, -5.1% from its 52-week high of $609.35, and has appreciated +8.1% over the 90-day period. At the company level, United Therapeutics shows solid fundamentals with latest-quarter revenue of $781,500,000.00, net income of $274,900,000.00, annual revenue growth of +10.6%, and a P/E of 19.07. As a scheduled 10b5-1 sale rather than a discretionary insider transaction, this filing reflects predetermined liquidity management rather than a real-time market signal and should be weighted accordingly in sentiment analysis.

CFO James Edgemond sold 10,000 shares (34.6% of holdings) for $5.6M via 7 scheduled transactions under a 10b5-1 plan

James Edgemond, CFO and Treasurer of United Therapeutics, executed 7 separate sales totaling 10,000 shares for $5,641,130.12 on 2026-05-21, reducing his holdings from 28.9K to 18.9K shares. The sales occurred at prices ranging from $557.85 to $566.12, with a blended average of $564.11, compared to the current price of $568.43. This sale was conducted under a pre-arranged 10b5-1 trading plan, indicating it was scheduled rather than discretionary. His prior trades at UTHR show a mixed return pattern, with 30d and 90d returns clustering near -0.5% to +0.1%, while his broader cross-ticker track record shows an average 90d return of -1.0% on prior sells.